Skip to main content
. Author manuscript; available in PMC: 2015 Jul 13.
Published in final edited form as: Immunol Cell Biol. 2014 Aug 12;93(1):67–76. doi: 10.1038/icb.2014.68

Table 1.

KIR3DL1+ and KIR3DS1+ CD8+ T cell response rates to different stimulations.

HIV peptides CMV peptides P815/anti-CD3
PBMC Uninfected controls
KIR3DL1++ HLA-Bw41 0/6 6/6
KIR3DL1++ HLA-Bw6 0/3 3/3
KIR3DS1++ 1/1 1/1
PBMC HIV-infected subjects
KIR3DL1++ HLA-Bw4 0/10 0/6 4/4
KIR3DL1++ HLA-Bw6 0/6 1/8 2/2
KIR3DS1++ 3/3 3/3 3/3
In vitro restimulation2 purified KIR3DL1++ Flu peptide
peptide + IL-2 + IL-7 0/4 2/2 1/1
Con A + IL-2 0/2 2/2
1

CD8+ KIR3DL1+ T cell responses against HIV or CMV peptides in PBMC from control and HIV-infected individuals with different genetic backgrounds and strong overall T cell responses against the corresponding peptides were assessed by surface and intracellular flow cytometry.

2

KIR3DL1+ cells purified from PBMC of KIR3DL1 homozygous individuals were restimulated with either specific peptides or mitogen (Con A) plus cytokines and the reactivity of expanded cells was tested against HIV, CMV or flu peptides by surface and intracellular flow cytometry.